You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Renal cancer

Nivolumab for previously treated advanced renal cell carcinoma

  • Technology appraisal guidance
  • Reference number: TA417
  • Published:  23 November 2016
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 Evidence
  • 4 Committee discussion
  • 5 Implementation
  • 6 Appraisal committee members and NICE project team
  • Update information

1 Recommendations

1.1

Nivolumab is recommended, within its marketing authorisation, as an option for previously treated advanced renal cell carcinoma in adults, when the company provides nivolumab according to the commercial arrangement.


Next page 2 The technology Previous page Overview
Back to top